Lion Dandelion Tea

Lion Dandelion Tea

Our story starts the morning after a night’s celebrations when LION founder Ray DeRosa woke up to blurry vision. He had triggered a mother-to-son inherited eye disease called Leber’s Neuropathy where your vision slowly declines in just a few days. While there was no known cure in modern medicine, that didn’t stop Ray and his mother from finding one themselves. They turned to plants and home made remedies and sure enough a cure was found in the dandelion. This common, backyard weed opened the doors to a whole new world of potential.

Min investment
$100
Goal
$60K-$250K
Days Left
13
Location
New York, NY

CrowdLustro Research Report

Security Type
SAFE
A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.
Industry
Food & Bev
Filed
March 03, 2021
Expires
April 30, 2021
Valuation Cap
$4M
Deal Structure

Price Per Share: $1.00

Use of Proceeds

$60,000

  • 55% towards production of LION Tea, 15% towards social media advertising, 22.5% towards salary for LION Team, 7.5% towards Wefunder fees.

$250,000

  • 40% towards production of LION Tea, 20% towards social media advertising, 32.5% towards salary for LION Team, 7.5% towards Wefunder fees.

Management

Raymond DeRosa, Founder & CEO
Starting LION Tea.

Mollie Vogt-Welch, Creative Director

Emily Stubler, Marketing Advisor

Research Reports

No reports have been submitted

Become a Reporter

Key Deal Facts

770% growth since Feb 2020
Acquired over 15,000 customers in 2020
22% repeat purchase rate making up 44% of our revenue
Dropped cost of acquisition by 40% in 4 months
Pivoted to direct to consumer and doubled our revenue in 2020.
Increased our gross margin to 60% in 2021
A delicious, tangible product with a fully built in customer base

0 Comments